Patterns of thyroid hormone levels in pediatric medullary thyroid carcinoma patients on vandetanib therapy
Authors:
- Maya LodishMLMaya Lodish
- Alexandra GkourogianniAGAlexandra Gkourogianni
- Ethan BornsteinEBEthan Bornstein
- Ninet SinaiiNSNinet Sinaii
- Elizabeth FoxEFElizabeth Fox
- Meredith ChukMCMeredith Chuk
- Leigh MarcusLMLeigh Marcus
- Srivandana AkshintalaSASrivandana Akshintala
- Frank BalisFBFrank Balis
- Brigitte WidemannBWBrigitte Widemann
- Constantine A StratakisCSConstantine A Stratakis
Open Access
- 16 February 2015
- journal article
- research article
- Published by Springer Nature in International Journal of Pediatric Endocrinology
- Vol. 2015 (1) , 3
Abstract
Tyrosine kinase inhibitors (TKIs) have been associated with elevated TSH as a drug class effect. Prior studies of vandetanib in adults with medullary thyroid carcinoma (MTC) described an increase in levothyroxine (LT) requirement. We studied TSH, free T4, and LT dosing in children and adolescents enrolled in the phase I/II trial of vandetanib for medullary thyroid cancer (MTC) Data from 13 patients with multiple endocrine neoplasia type 2B (MEN 2B) and MTC were analyzed [6 M, 7 F, median age 13.0 y (9.1-17.3)] Eleven patients (85%) had undergone prior thyroidectomy and all received single-drug therapy with vandetanib for > 6 months. Confirmed compliance with vandetanib (67–150 mg/m2/day) and LT was a necessary inclusion criterion. While on vandetanib treatment, all 11 athyerotic patients exhibited significantly increased TSH levels. The baseline TSH level was 4.37 mclU/ml (0.08 - 23.30); in comparison, the first peak TSH concentration on vandetanib was 15.70 mclU/ml (12.50 - 137.00, p = 0.0010). The median time to reach the initial peak of elevated TSH was 1.8 months (0.3 - 9.3). Free T4 levels remained within the normal reference range. An increase from a baseline LT dose of 91 mcg/m2/day (±24) to 116 mcg/m2/day (±24) was required in order to resume normative TSH levels (p = 0.00005), equal to an increase of 36.6% (±16.56) in the dosage of LT in mcg/day. For the 2 patients with intact thyroid glands, free T4 and TSH remained normal over a combined 6 patient years of follow up. In our cohort of pediatric MTC patients, athyreotic patients with preexisting hypothyroidism developed increased TSH and reduced free T4 during the first few months of treatment with vandetanib, necessitating an increase in LT dosage. Additional patients with normal thyroid function before treatment and intact glands (n = 2) maintained normal thyroid function tests during treatment. Elevated TSH in athyreotic patients may be due to an indirect effect of vandetanib on the metabolism of thyroid hormone, or to altered TSH sensitivity at the pituitary. Proper recognition and management of abnormal thyroid hormone levels is critical in growing children on TKIs. ClinicalTrials.gov Identifier: NCT00514046Keywords
This publication has 24 references indexed in Scilit:
- Kinase Inhibitors: Adverse Effects Related to the Endocrine SystemThe Journal of Clinical Endocrinology & Metabolism, 2013
- Inappropriate Elevation of Serum Thyrotropin Levels in Patients Treated with AxitinibThyroid®, 2013
- Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and managementTargeted Oncology, 2011
- Sunitinib-Induced Hypothyroidism Is due to Induction of Type 3 Deiodinase Activity and Thyroidal Capillary RegressionThe Journal of Clinical Endocrinology & Metabolism, 2011
- Endocrine Effects of the Tyrosine Kinase Inhibitor Vandetanib in Patients Treated for Thyroid CancerThe Journal of Clinical Endocrinology & Metabolism, 2011
- Influence of lymph node metastases on survival in pediatric medullary thyroid cancerJournal of Pediatric Surgery, 2010
- Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474Endocrine-Related Cancer, 2009
- Time trends of cancer incidence in European children (1978–1997): Report from the Automated Childhood Cancer Information System projectEuropean Journal of Cancer, 2006
- Imatinib induces hypothyroidism in patients receiving levothyroxineClinical Pharmacology & Therapeutics, 2005
- Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitorsOncogene, 2004